UMIN ID: UMIN000018995
Registered date:01/10/2015
Metformin therapy for East Asian women with recent gestational diabetes mellitus and glucose abnormalities: a multicenter, randomized, open-label trial
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Women with recent gestational diabetes mellitus (GDM) and glucose abnormalities, including impaired fasting glucose (IFG), or impaired glucose tolerance (IGT), or both (IFG, IGT) postpartum. |
Date of first enrollment | 2015/10/01 |
Target sample size | 210 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | <Standard lifestyle intervention alone> The standard lifestyle intervention will include the provision of individual advice on diet and exercise for 24 months. Patients diagnosed with diabetes will be withdrawn. <Standard lifestyle intervention plus metformin > The standard lifestyle intervention will include the provision of individual advice on diet and exercise. Treatment with metformin will be initiated at a dose of 500mg taken orally twice a day, and will be increased to 1500mg daily, unless gastrointestinal symptoms occur. Standard lifestyle intervention plus metformin therapy will continue for 24 months. Patients diagnosed with diabetes will be withdrawn. |
Outcome(s)
Primary Outcome | Period of progression to type 2 diabetes mellitus |
---|---|
Secondary Outcome | 1.Change in blood glucose and serum insulin levels determined by a 75g oral glucose tolerance test (OGTT) 2.Change in index of insulin sensitivity (Matsuda index) from baseline and at study end (24 months after initiation of therapy, or the final point to be observed) 3.Change in index of insulin resistance (HOMA-IR)from baseline and at study end (24 months after initiation of therapy, or the final point to be observed) 4.Change in index of beta-cell function (Disposition index, Insulinogenic index) from baseline and at study end (24 months after initiation of therapy, or the final point to be observed) 5.Change in blood pressure, lipid metabolism, and body weight from baseline 6.Improvement to normal glucose tolerance 7.Incidence rate of adverse events |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | Not applicable |
Gender | Female |
Include criteria | |
Exclude criteria | (1)currently lactating; (2)planning to conceive in the next two years; (3)a history of diabetes and prior use of metformin or insulin to treat diabetes; (4)a history of lactic acidosis; (5)renal impairment (serum creatinine (Cr) level >=1.2mg/dl, including dialysis patients); (6)severe liver dysfunction (serum aspartate transaminase (AST) and/or aminotransferase (ALT) level exceeding more than a threefold increase in normal lab values); (7)cardiac failure, cardiac infarction, pulmonary embolism, a high degree of failure in lung function, and hypoxemia; (8)excessive alcohol intake; (9)malnutrition, or are in a state of starvation or debility, or have pituitary malfunction or adrenal insufficiency; (10)a history of hypersensitivity reaction to metformin or other biguanides; (11)thyroid function that is not controlled by hyperthyroidism (serum free thyroxine (fT4) levels exceed normal lab values within three months); (12)autoantibody-positive status (e.g. GAD, IA-2), or suspected diabetes mellitus associated with a mutation of mitochondrial DNA, maternally inherited diabetes and deafness (MIDD), or MODY (maturity-onset diabetes of the young); (13) not considered eligible to participate in this study by the attending doctor due to other reasons. |
Related Information
Primary Sponsor | National Center for Child Health and Development, Tokyo, Japan |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | National Center for Child Health and Development, Tokyo, Japan |
Secondary ID(s) |
Contact
public contact | |
Name | Maki Kawasaki |
Address | 10-1,Okura,2 chome,Setagaya,Tokyo,157-8538,JAPAN Japan |
Telephone | 03-3416-0181(7954) |
boseinaika@ncchd.go.jp | |
Affiliation | National Center for Child Health and Development, Tokyo, Japan Maternal Medicine |
scientific contact | |
Name | Naoko Arata |
Address | 10-1,Okura,2 chome,Setagaya,Tokyo,157-8538,JAPAN Japan |
Telephone | 03-3416-0181(7011) |
boseinaika@ncchd.go.jp | |
Affiliation | National Center for Child Health and Development, Tokyo, Japan Maternal Medicine |